Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features

Cancer Causes and Control

Volumn 27, Issue 1, 2016, Pages 81-91

  VanValkenburg, MaryAnn E ^a   Pruitt, Gwendolyn I ^b   Brill, Ilene K ^b   Costa, Luciano ^c,d   Ehtsham, Maryam ^b,e   Justement, Ian T ^b,e   Innis Shelton, Racquel D ^c,d   Salzman, Donna ^c,d   Reddy, E Shyam P ^f   Godby, Kelly N ^c,d   Mikhail, Fady M ^g   Carroll, Andrew J ^g   Reddy, Vishnu B ^a,d   Sanderson, Ralph D ^a,d   Justement, Louis B ^d,h   Sanders, Paul W ^d,i,j   Brown, Elizabeth E ^a,d,k  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^f MOREHOUSE SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h University of Alabama at Birmingham   (United States)

ⁱ University of Alabama at Birmingham   (United States)

^j BIRMINGHAM VA MEDICAL CENTER   (United States)

^k NONE   (United States)

more..

Author keywords

African American; Black; Family history; Genetic; Multiple myeloma

Indexed keywords

IMMUNOGLOBULIN KAPPA CHAIN;

ADULT; AGED; ARTICLE; BLACK PERSON; CANCER RISK; CANCER SUSCEPTIBILITY; CAUCASIAN; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; GENOTYPE ENVIRONMENT INTERACTION; GERMLINE MUTATION; HEMATOLOGIC MALIGNANCY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; ONSET AGE; ORGAN INJURY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RACE DIFFERENCE; RELATIVE; RISK ASSESSMENT; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; HEMATOLOGIC NEOPLASMS; INCIDENCE; MIDDLE AGED; RISK;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RISK;

EID: 84953365119     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-015-0685-2     Document Type: Article

References (42)

1. Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 351:1860–1873
2. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300
3. Landgren O, Kyle RA, Pfeiffer RM et al (2009) Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113:5412–5417
4. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM (2009) A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113:5418–5422
5. Kyle RA, Therneau TM, Rajkumar SV et al (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346:564–569
6. Greenberg AJ, Rajkumar SV, Vachon CM (2012) Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics. Blood 119:5359–5366
7. Landgren O, Gridley G, Turesson I et al (2006) Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 107:904–906
8. Landgren O, Katzmann JA, Hsing AW et al (2007) Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc 82:1468–1473
9. Waxman AJ, Mink PJ, Devesa SS et al (2010) Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 116:5501–5506
10. Horwitz LJ, Levy RN, Rosner F (1985) Multiple myeloma in three siblings. Arch Intern Med 145:1449–1450
11. Lynch HT, Thome SD (2009) Familial multiple myeloma. Blood 114:749–750
12. Lynch HT, Watson P, Tarantolo S et al (2005) Phenotypic heterogeneity in multiple myeloma families. J Clin Oncol 23:685–693
13. Roddie PH, Dang R, Parker AC (1998) Multiple myeloma in three siblings. Clin Lab Haematol 20:191–193
14. Grosbois B, Jego P, Attal M et al (1999) Familial multiple myeloma: report of fifteen families. Br J Haematol 105:768–770
15. Hemminki K, Li X, Czene K (2004) Familial risk of cancer: data for clinical counseling and cancer genetics. Int J Cancer 108:109–114
16. Bourguet CC, Grufferman S, Delzell E, Delong ER, Cohen HJ (1985) Multiple myeloma and family history of cancer a case–control study. Cancer 56:2133–2139
17. Eriksson M, Hållberg B (1992) Familial occurrence of hematologic malignancies and other diseases in multiple myeloma: a case–control study. Cancer Causes Control 3:63–67
18. Altieri A, Chen B, Bermejo JL, Castro F, Hemminki K (2006) Familial risks and temporal incidence trends of multiple myeloma. Eur J Cancer 42:1661–1670
19. Kristinsson SY, Björkholm M, Goldin LR et al (2009) Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. Int J Cancer 125:2147–2150
20. Brown LM, Linet MS, Greenberg RS et al (1999) Multiple myeloma and family history of cancer among blacks and whites in the US. Cancer 85:2385–2390
21. Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538–e548
22. Greipp PR, San Miguel J, Durie BG et al (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412–3420
23. Howard VJ, Cushman M, Pulley L et al (2005) The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology 25:135–143
24. Simpson NK, Johnson CC, Ogden SL et al (2000) Recruitment strategies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: the first six years. Control Clin Trials 21:356S–378S
25. Chang ET, Smedby KE, Hjalgrim H, Glimelius B, Adami HO (2006) Reliability of self-reported family history of cancer in a large case–control study of lymphoma. J Natl Cancer Inst 98:61–68
26. Camp NJ, Werner TL, Cannon-Albright LA (2008) Familial myeloma. N Engl J Med 359:1734–1735
27. Altieri A, Bermejo JL, Hemminki K (2005) Familial risk for non-Hodgkin lymphoma and other lymphoproliferative malignancies by histopathologic subtype: the Swedish Family-Cancer Database. Blood 106:668–672
28. Wang SS, Slager SL, Brennan P et al (2006) Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10,211 cases and 11,905 controls from the InterLymph Consortium. Blood 109:3479–3488
29. Broderick P, Chubb D, Johnson DC et al (2012) Common variation at 3p22. 1 and 7p15. 3 influences multiple myeloma risk. Nat Genet 44:58–61
30. Chubb D, Weinhold N, Broderick P et al (2013) Common variation at 3q26. 2, 6p21. 33, 17p11. 2 and 22q13. 1 influences multiple myeloma risk. Nat Genet 45:1221–1225
31. Weinhold N, Johnson DC, Chubb D et al (2013) The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat Genet 45:522–525
32. Pottern LM, Gart JJ, Nam JM et al (1992) HLA and multiple myeloma among black and white men: evidence of a genetic association. CEBP 1:177–182
33. Schoenfeld Y, Berliner S, Shaklai M, Gallant LA, Pinkhas J (1982) Familial multiple myeloma. A review of 37 families. Postgrad Med J 58:12–16
34. Brown LM, Gridley G, Check D, Landgren O (2008) Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 111:3388–3394
35. Hemminki K, Liu X, Forsti A, Ji J, Sundquist J, Sundquist K (2012) Effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma. J Hematol Oncol 5:59
36. Landgren O, Linet MS, McMaster ML, Gridley G, Hemminki K, Goldin LR (2006) Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case–control study. Int J Cancer 118:3095–3098
37. Lindqvist EK, Goldin LR, Landgren O et al (2011) Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. Blood 118:6284–6291
38. McShane CM, Murray LJ, Landgren O et al (2014) Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic review. CEBP 23:332–342
39. Baris D, Brown LM, Silverman DT et al (2000) Socioeconomic status and multiple myeloma among US blacks and whites. Am J Public Health 90:1277–1281
40. Bjornsson HT, Cui H, Gius D, Fallin MD, Feinberg AP (2004) The new field of epigenomics: implications for cancer and other common disease research. Cold Spring Harb Symp Quant Biol 69:447–456
41. Bjornsson HT, Fallin MD, Feinberg AP (2004) An integrated epigenetic and genetic approach to common human disease. Trends Genet 20:350–358
42. Feinberg AP (2007) Phenotypic plasticity and the epigenetics of human disease. Nature 447:433–440